The activating mutation BRAF T1796A is the most prevalent genetic alteration in papillary
thyroid carcinomas (PTC). It is associated with advanced PTCs, suggesting that this …

Abstract Context: Although the BRAF V600E mutant can initiate the formation of papillary
thyroid cancer (PTC), it is unclear whether it is required to maintain cell proliferation …

Mutated BRAF is detected in approximately 45% of papillary thyroid carcinomas (PTC). To
model PTC, we bred mice with adult-onset, thyrocyte-specific expression of BRAFV600E …

The BRAFT1799A mutation is the most common genetic alteration in papillary thyroid
carcinomas (PTC). It is also found in a subset of papillary microcarcinomas, consistent with a …

Background: The mutated BRAF V600E protein has been specifically detected in papillary
thyroid carcinomas (PTCs) using immunohistochemical (IHC) analysis. The clonal origin of …

Activating mutations of the BRAF gene are the most common genetic alterations in papillary
thyroid carcinomas (PTCs) and the T1799A transversion, resulting in BRAF V600E …

Papillary thyroid cancer (PTC) is the most common endocrine malignancy, accounting for 85–
90% of all thyroid cancers. Genetic alternations involving the mitogen-activated protein …

Context: BRAFV600E is considered a primary event, a negative prognostic marker, and a
site for pharmacological intervention in papillary thyroid carcinoma (PTC). We asked …

Context: The homogeneous distribution of BRAF V600E in papillary thyroid carcinoma (PTC)
has been called into question by recent reports. These studies claim that BRAF V600E is …

Activating point mutations of the BRAF gene have been recently reported in papillary thyroid
carcinomas. In this study, we analyzed 320 thyroid tumors and six anaplastic carcinoma cell …